QIAGEN Companion Diagnostic Wins FDA Approval for use With IRESSA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Maintains a Neutral Rating on Qiagen (QGEN) Following Expanded Channel Checks
July 14, 2015 8:02 AM EDTPiper Jaffray maintains a Neutral rating and $24.00 price target on Qiagen NV (NASDAQ: QGEN) following expanded channel checks. Analyst William Quirk says that the latest checks did not uncover additional transitions from Qiagen to alternative HPV platforms, and views this as a sighn that shares are stabilizing.
Quirk commented,... More
Qiagen (QGEN) Announces Receipt of FDA PMA for Therascreen EGFR Test for Use with IRESSA in NSCLC
July 13, 2015 3:47 PM EDTQiagen (NASDAQ: QGEN) received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca' (NYSE: AZN) IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN's therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with... More
